All In Biotech

Drug Trial Radar · NCT06008106

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Efficacy and Safety of Tunlametinib Capsules Versus Combination Chemotherapy of Investigator's Choice in Advanced NRAS-mutant Melanoma Patients Who Had Previously Received Immunotherapy

Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Nov 2, 2023

Primary completion

Sep 22, 2027

Study completion Sep 22, 2027

Sponsor

Lead sponsor
Shanghai Kechow Pharma, Inc.Industry
Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in advanced melanoma patients with NRAS mutation who have received immunotherapy before. Subjects were stratified according to the baseline lactate dehydrogenase level and chemotherapy.

Conditions

  • Melanoma

Interventions

  • tunlametinibDrug

    12mg BID

  • paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatinDrug

    according to investigators' suggestion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival(PFS)Time frame: up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.